Nicholas J. Laping

SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7

Gareth J. Inman, Francisco José Nicolás, James F. Callahan et al. · Molecular Pharmacology · 2002 · 1.7K citations

Life Sciences, Molecular Biology, Pharmacology +13

Inhibition of Transforming Growth Factor (TGF)-β1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542

Nicholas J. Laping, Eugene T. Grygielko, Anil Mathur et al. · Molecular Pharmacology · 2002 · 650 citations

Life Sciences, Molecular Biology, Pharmacology +16

GFAP mRNA increases with age in rat and human brain

Nancy R. Nichols, Jonathan Day, Nicholas J. Laping et al. · Neurobiology of Aging · 1993 · 419 citations

Medicine, Neurobiology, Neuroscience +14

SB-505124 Is a Selective Inhibitor of Transforming Growth Factor-β Type I Receptors ALK4, ALK5, and ALK7

Stacey DaCosta Byfield, Christopher Major, Nicholas J. Laping et al. · Molecular Pharmacology · 2004 · 416 citations

Life Sciences, Medicinal Chemistry, Pharmacology +13

N-((1 S)-1-{[4-((2 S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a Novel and Potent Transient Receptor Potential Vanilloid 4 Channel Agonist Induces Urinary Bladder Contraction and Hyperactivity: Part I

Kevin S. Thorneloe, Anthony C. Sulpizio, Zuojun Lin et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 404 citations

Medicine, Pharmacology, Physiology +16